Aerosol Drug Delivery

Aerosol drug delivery represents an attractive non-invasive method for local and systemic drug delivery that targets airways as the specific absorption regions. The importance of drug delivery through pulmonary and nasal routes has grown significantly in recent years as the lung and nose are potential sites for delivery of biological drugs, including proteins, peptides, and RNAs.

Aerosol administration requires specialized devices, such as nebulizers, pressurized metered-dose inhalers, and dry powder inhalers. Beyond drug-excipient interactions, understanding the formulation-device interface remains critical for effective drug delivery.

Work Package Development

At the inception of SweDeliver, pulmonary drug delivery expertise was limited at Uppsala University’s Faculty of Pharmacy. The decision to establish a dedicated Work Package stemmed from recognition of the well-established capabilities within the academic team in the area of powder technology and solid dosage formulation—foundational skills for inhaled formulations where particle properties are critical for performance. Moving on to the next phase (SweDeliver 2.0), the Swedeliver Aerosol Drug Delivery work package strives to conduct state-of-the-art and internationally competitive research on all administration routes and forms of aerosols.

Professor Albert Mihranyan leads the academic research efforts in collaboration with industrial partners, including researchers from AstraZeneca, Cheisi, Orexo, Ferring, Caliditas and MVIC AB. The work package further maintains collaborations with national initiatives such as Swedish Inhalation Network (SwedIN), enhancing visibility within this research domain.